SEC Form 4 · accession 0001104659-16-146915
Amphastar Pharmaceuticals, Inc. · AMPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason B. Shandell
Officer — President and General Counsel · Director
Period of report
Sep 26, 2016
Accepted (ET)
Sep 27, 2016 · 6:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001297184
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 26, 2016 | M | 56,996 | $10.93 | A | 259,957 | D | |
| Common StockF2 | Sep 26, 2016 | S | 56,996 | $19.4973 | D | 202,961 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F3 | $10.93 | Sep 26, 2016 | M | 56,996 | D | — | Jul 5, 2023 | Common Stock | 56,996 | 94,992 | D |
Explanation of responses
- F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2016.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.26 to $20.11 inclusive. The reporting person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F3Shares subject to the option vest in four equal annual installments beginning on July 5, 2014.